drugset

drugset / Trial / NCT06775340

Study of RSS0343 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

NCT06775340 ↗

Phase 2 Recruiting 252 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Studies to evaluate the safety, tolerability, pharmacodynamics, and efficacy of RSS0343 tablets in patients with non-cystic fibrosis bronchiectasis

Timeline

Start: 2025-01-22
Primary completion: 2027-11
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RSS0343	Unknown	—	Oral

Indications